GlaxoSmithKline Catches Analysts Sleeping Again

Before you go, we thought you'd like these...
Before you go close icon

GlaxoSmithKline (NYS: GSK) reported earnings on July 25. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended June 30 (Q2), GlaxoSmithKline missed estimates on revenue and missed estimates on earnings per share.

Compared to the prior-year quarter, revenue dropped and GAAP earnings per share improved.


Gross margins dropped, operating margins dropped, and net margins grew.

Revenue details
GlaxoSmithKline reported revenue of $10.14 billion. The 10 analysts polled by S&P Capital IQ hoped for net sales of $10.45 billion on the same basis. GAAP reported sales were 6.1% lower than the prior-year quarter's $10.79 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.82. The one earnings estimate compiled by S&P Capital IQ predicted $0.86 per share. GAAP EPS of $0.39 for Q2 were 11% higher than the prior-year quarter's $0.35 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 69.2%, 660 basis points worse than the prior-year quarter. Operating margin was 26.9%, 240 basis points worse than the prior-year quarter. Net margin was 19.4%, 290 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $10.90 billion. On the bottom line, the average EPS estimate is $0.96.

Next year's average estimate for revenue is $42.62 billion. The average EPS estimate is $3.84.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 29 members out of 34 rating the stock outperform, and five members rating it underperform.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on GlaxoSmithKline is outperform, with an average price target of $48.52.

The article GlaxoSmithKline Catches Analysts Sleeping Again originally appeared on Fool.com.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners